PlainRecalls
ModerateClass IITerminated

FDA Drug recall · Reported January 16, 2019

Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)100mL (NDC 68180-722-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA

CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

Recall #
D-0375-2019
Affected scope
287,784 bottles
Initiated
January 2, 2019
Verify with FDA Drug →
View my saved recalls

Lupin Pharmaceuticals Inc. recalled Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)10… - a moderate-severity action.

Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)10… was recalled by Lupin Pharmaceuticals Inc. in January 16, 2019. Reason: CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.. Check the official notice for the remedy. Verify recall #D-0375-2019 with the FDA Drug before acting.

The recall

Lupin Pharmaceuticals Inc. issued this moderate-severity FDA Drug recall-CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick..

Moderate
severity level
Class II
classification
January 16, 2019
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0375-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,472 drugs & medications recalls on record

05001,0001,5002,000 2006201220152018202120242026 448
Severity1906864652High severity (most serious)Moderate severityLow severity
Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)100mL (NDC 68180-722-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA

Reason for recall

CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Terminated
Recall number D-0375-2019
Date reported January 16, 2019
Date initiated January 2, 2019
Recalling firm Lupin Pharmaceuticals Inc.
Firm location Baltimore, MD
Affected scope 287,784 bottles
Distribution Nationwide within the United States

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0375-2019) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)100mL (NDC 68180-722-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA. Recalled by Lupin Pharmaceuticals Inc.. Units affected: 287,784 bottles.
Why was this product recalled?
CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 16, 2019. Severity: Moderate. Recall number: D-0375-2019.
Where was the recalled product distributed?
Distribution: Nationwide within the United States.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported January 16, 2019. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026